ArticleTherapeutic advances in gastroenterology2022

Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.

Aviv Pudipeddi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.